​The Lung Site Group at Princess Margaret aims to continuously advance the frontiers of clinical and translational research to provide innovative treatment and management in medical, radiation and surgical oncology.

Our translational lung cancer research program received grant support for its continued growth this year. The program explores tumour markers, molecular pathology of targeted therapies and selection of therapy on the basis of molecular targets.

A number of investigators lead the program, including the globally recognized Dr. Frances Shepherd and Dr. Ming Tsao, with grants from the Ontario Institute of Cancer Research, Canadian Cancer Society and Terry Fox Research Institute and recipients of the Ontario Premier’s Summit Award for Research Excellence.

Dr. Geoffrey Liu holds a Research Chair in Experimental Therapeutics and Population Studies at Cancer Care Ontario. Doctors Natasha Leighl, Thomas Waddell, Gilda Santos and others are all part of the translational lung cancer program at Princess Margaret Cancer Centre.

The Lung Site Group is grateful to the Princess Margaret Cancer Foundation and the many donors who support research and innovation at our centre. These include numerous endowed fellowships, research funds and academic research chairs, including the following:

Endowed Princess Margaret Cancer Centre Chairs:
  • Scott Taylor Chair in Lung Cancer Research
  • M. Qasim Choksi Chair in Lung Cancer Translational Research
  • Alan B. Brown Chair in Molecular Genomics
  • Addie MacNaughton Chair in Thoracic Radiation Oncology
  • OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development
Endowed Toronto General Hospital Chairs:
  • James Wallace McCutcheon Chair in Surgery
  • Pearson-Ginsberg Chair in Thoracic Surgery
  • Thomson Family Chair in Thoracic Translational Research
  • Kress Family Chair in Esophageal Cancer
Endowed Fellowships:
  • Oberlander Fellowship in Lung Cancer Research
  • Michael V. and Wanda Plachta Fellowship in Thoracic Surgical Oncology
​​

Open Clinical Trials

 
NCT and Other Names
 
Title
 
Principal Investigator
 
Disease Location
Mesothelioma
NCT05380713
21-6216
......SMARTEST Trial......Dr. Marc de PerrotMesothelioma
NCT06097728
D7988C00001, 2023-503231-17-00,2023-000067-32
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaDr. Penelope BradburyMesothelioma
Multiple Sites
NCT05789082
BO44426, 2022-003048-28,2023-507171-22-00
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationDr. Adrian SacherMultiple Sites
NCT05094336
20210023, 2023-504363-17
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Dr. Adrian SacherMultiple Sites
NCT05067283
1084-001, MK-1084-001,jRCT2041220034,2022-501563-40-00,U1111-1281-2482
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)Dr. Adrian SacherMultiple Sites
NCT06333951
20230167
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Dr. Adrian SacherMultiple Sites
NCT04534413
20-5565
Ex-Vivo COF Study for Lung Cancer ObservationDr. Kazuhiro YasufukuMultiple Sites
NCT04782752
20-5902
Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As RadiovaccinationDr. Marc de PerrotMultiple Sites
NCT03356743
16-6177
Spectrum Analysis in Ex-vivo Human LungsDr. Kazuhiro YasufukuMultiple Sites
NCT03349307
16-6083
Thin-EBUS in Ex-vivo Human LungsDr. Kazuhiro YasufukuMultiple Sites
Non Small Cell Lung Cancer (NSCLC)
NCT05221840
D9078C00001, 2023-503999-24-00,2021-004346-37
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerDr. Frances ShepherdNon Small Cell Lung Cancer (NSCLC)
NCT05975073
20220127
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid TumorsDr. Adrian SacherNon Small Cell Lung Cancer (NSCLC)
NCT06497556
BO45217, 2024-510908-37-00
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerDr. Adrian SacherNon Small Cell Lung Cancer (NSCLC)
NCT06077760
V940-002, 2023-504923-20-00,U1111-1290-3969,jRCT2061240063,PHRR240705-007252
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Dr. Marc de PerrotNon Small Cell Lung Cancer (NSCLC)
NCT05118789
NVL-520-01
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)Dr. Geoffrey LiuNon Small Cell Lung Cancer (NSCLC)
NCT04449874
GO42144, 2020-000084-22,2023-506311-18-00
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationDr. Adrian SacherNon Small Cell Lung Cancer (NSCLC)
NCT06417814
D516KC00001, 2024-511362-37-00
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerDr. Natasha LeighlNon Small Cell Lung Cancer (NSCLC)
NCT05048797
D967SC00001, 2023-503674-20-00,2021-000634-33
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsDr. Penelope BradburyNon Small Cell Lung Cancer (NSCLC)
NCT06452277
22615, 2024-511319-91-00
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Dr. Natasha LeighlNon Small Cell Lung Cancer (NSCLC)
NCT04614103
IOV-LUN-202, 2020-003629-45,2024-510778-26-00
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerDr. Adrian SacherNon Small Cell Lung Cancer (NSCLC)
 
Page of 3
View 1 - 20 of 42

To refer a patient to a clinical trial, complete a new patient referral form. Learn more about the Princess Margaret referral process »

For patients: Are you considering taking part in a clinical trial? Learn more about how and why clinical trials are done and what you can expect if you decide to take part in a trial »

https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx
Last reviewed: 8/27/2017
Last modified: 10/30/2023 1:03 PM
Back to Top